CAdVEC
AXP000042.1 · Oncolytic virus
- Platform
- adenovirus (binary oncolytic adenovirus, helper-dependent)
- Originator
- Baylor College of Medicine
- Sponsor
- Baylor College of Medicine
Names
| Name | Type | Source |
|---|---|---|
| CAdVEC | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- binary oncolytic adenovirus (CAdVEC)
- Replication
- conditionally replicating
- Modifications
- helper-dependent binary oncolytic adenovirus system
- Transgenes
- IL12A, IL12B, anti-PD-L1 mini-antibody
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C158743
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Recruiting | Phase 1 | 2020-12-14 | 2026-12-30 | 45 | Bladder Cancer; Breast Cancer; Cancer of the Salivary Gland; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Lung Cancer; Pancreatic Adenocarcinoma; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38993326 | Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity. | Molecular therapy. Methods & clinical development | 2024 | name in abstract: CAdVEC |
| PMID 39653552 | Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. | Journal for immunotherapy of cancer | 2024 | name in abstract: CAdVEC |
| PMID 36989357 | Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. | Science advances | 2023 | name in abstract: CAdVEC |
Notes
Oncolytic adenovirus engineered to express IL-12 and an anti-PD-L1 mini-antibody, given intratumorally and followed by autologous HER2-specific CAR T cells (NCT03740256). The CAR T product is a separate program, not entered here.
How to cite
CAdVEC (AXP000042.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000042.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.